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Background: Solitary lung metastasis from prostate cancer is rare. There are few reports of such cases with
neuroendocrine differentiation.
Case presentation: A 50-year-old man presented to our hospital with a chief complaint of dysuria. Histological
examination revealed prostate cancer, which was classified as cT4 N0 M0, stage IV adenocarcinoma. Since the
patient was at high risk, endocrine and radiation therapies were started. One year after starting radiation therapy,
the patient developed bloody sputum. Chest radiography revealed a nodular shadow in his left lung (S5). Although
18-fluoro-2-deoxyglucose positron emission tomography revealed abnormal accumulation in the lesion, the
cytological diagnosis was class IIIa, which did not yield a definitive diagnosis. Given that prostate specific antigen
(PSA) was not elevated, a primary lung tumor was suspected, and thoracoscopic segmental resection of the lung
was performed with lymph node dissection. The final pathological diagnosis was solitary lung metastasis from
prostate cancer with neuroendocrine differentiation and mediastinal lymph node metastasis. The specimen showed
a mixed pattern of conventional prostatic and neuroendocrine carcinomas.
Conclusion: We herein report a case with neuroendocrine differentiation (NED), along with a review of the relevant
literature, including histopathological findings. According to previous case reports, some patients with solitary lung
metastasis from prostate cancer achieved relatively good long-term survival. We consider establishing the correct
diagnosis and implementing an appropriate treatment plan to be essential in prostate cancer patients with
oligometastases that have the potential to be neuroendocrine (NE) tumors.
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Solitary lung metastasis from prostate cancer is rare. To
date, only 22 cases have been reported (including our
present patient). There are few reports of such cases
with neuroendocrine differentiation (NED). NED in
prostate carcinoma occurs in the form of a small cell
carcinoma, carcinoid or carcinoid-like tumor, and as
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unless otherwise stated.[1]. Neuroendocrine (NE) cells exist in the normal pros-
tate and are considered to be involved in the differenti-
ation and proliferation of prostatic cells through various
growth factors, without mediation by androgen recep-
tors (AR) [1]. In addition, NE tumors can be classified
according to the conditions at the time of detection into
three types as follows: pure NE prostate carcinoma at
the time of initial examination, mixed pattern of conven-
tional and NE prostatic carcinomas at the time of initial
examination, and NE carcinoma (NEC) developing during
endocrine therapy [2]. We herein report a case with NED,ntral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cases, including histopathological findings.
Case presentation
A 50-year-old man presented with a chief complaint of
dysuria. At the Outpatient Ward of our hospital, he was
clinically suspected of having prostatic cancer based on
the results of various clinical examinations including a
high prostate-specific antigen (PSA, 61.77 ng/ml) value.
A prostatic needle biopsy was thus performed. Histopatho-
logically, the biopsy specimens showed adenocarcinoma
forming medium to small glandular and cord-like struc-
tures. The patient was thus diagnosed as having a poorly
differentiated conventional prostate adenocarcinoma with
a Gleason score of 4 + 5 = 9 (Figure 1A, B). According to
the imaging and biopsy findings, the tumor was classified
as cT4 N0 M0, stage IV.
Cystoscopic examination revealed an erythematous vel-
vety appearance of the bladder mucosa, indicating that the
tumor was attributable to direct infiltration of prostate
carcinoma, consistent with the classification cT4 N0 M0,
stage IV. The patient was considered to be at a high risk
for the spread of prostatic cancer, and endocrine therapy
was started using goserelin acetate and bicalutamide. One
month after starting this endocrine therapy, the patient
underwent local radiation treatment at a dose of 66 Gy.
After these endocrine and radiation therapies, his PSA
levels gradually decreased but remained above the upper
limit of the reference range.
One year after starting radiation therapy, the patient
developed bloody sputum. A computed tomographic
scan showed 3-cm nodes, with spicula, notch, and pleural
indentation, in the lingual segment of the left lung
(Figure 2A, B). We then applied 18-fluoro-2-deoxyglu-
cose positron emission tomography which revealed se-
lective accumulation in the nodes, strongly suggesting a
malignant tumor. Given that the PSA level was not
markedly elevated, the patient was suspected to have aFigure 1 Histopathology of the prostatic needle biopsy at the time of initi
and cord-like structures, corresponding to Gleason score 4 + 5 = 9, is seenprimary lung tumor and underwent thoracoscopic seg-
mental resection of this portion of the lung with lymph
node dissection. Histopathological examination of the
resected lung revealed a neoplastic lesion. The tumor
was highly cellular and composed of eosinophilic tumor
cells with swollen ovale nuclei and prominent nucleoli.
The tumor cells exhibited a sheet-like pattern, and a
partly glandular pattern, of growth (Figure 3A, B). Fur-
thermore, the tumor cells proliferated along the alveolar
septae, replacing the alveolar lining epithelial cells. There
was no evidence of pleural infiltration of the tumor cells.
Immunohistochemical analysis results were positive for
not only PSA (Figure 4A) but also chromogranin, synap-
tophysin (Figure 4C), and CD56/CD57 (Figure 4D),
suggesting NED. None of the tumor cells was immuno-
positive for surfactant apoprotein (Figure 4B) or CK20/
CK7. Therefore, although this tumor with NED prolifer-
ated along the alveolar septae and showed a relatively
infrequent glandular pattern of growth, we considered
the lung tumor to be a solitary pulmonary metastasis
from prostate adenocarcinoma.
The patient subsequently received chemotherapy. In
this case, relatively high doses of paclitaxel (120 mg/
m2) and carboplatin (dosed to a target area under the
concentration-time curve [AUC] of 6.0) were adminis-
tered every 4 weeks for 2 cycles. After adjuvant chemo-
therapy, the patient was treated with irradiation of the
entire mediastinal field at a dose of 60 Gy with a boost
field of 10Gy. Thereafter, the patient developed systemic
metastases and received both chemotherapy and radiation
therapy for multiple lesions. He survived for approxi-
mately 30 months before dying of systemic metastases.
Discussion
The incidence of lung metastasis from prostate cancer
reported ranges from 5% to 27% [3]. Fabozzi et al. re-
ported the incidence of solitary lung metastasis from pros-
tate cancer to be only 0.86% [3]. Our search of PubMedal examination. Conventional prostate adenocarcinoma with tubular
in the specimen (A, ×100; B, ×200).
Figure 2 Plain computed tomographic image (lung window) showing the nodes with spicula (arrowhead), notch (arrow), and pleural indentation
in the lingual segment of the left lung. There is no evidence of calcification. (A) Lung window and (B) mediastinal window.
Maebayashi et al. World Journal of Surgical Oncology  (2015) 13:173 Page 3 of 7identified 46 articles with prostate cancer and solitary pul-
monary metastasis. In total, seven publications [4-10] on
cases similar to ours were identified, and all full texts were
retrieved. In total, 12 articles describing 22 cases were
identified, but we looked for 5 articles [3,11-14] from
references of past reports (Figure 5). To date, only 23
cases (including our present patient) with solitary lung
metastasis from prostate cancers have been reported
(Table 1) [3-14]. The present patient is the first, to our
knowledge, with solitary lung metastasis from prostate
cancer with NED.
In the early years of the study of this tumor type,
endocrine tumors were designated differently depending
on the site of origin. In 1907, Oberndorfer proposed the
name ‘carcinoid’ for endocrine tumors that develop in
the gastrointestinal tract [15]. Then, the idea that these
tumors arise from endocrine cells and disperse through-
out the body gained acceptance and led to a shared rec-
ognition of carcinoid and other endocrine tumors. In
2004, the World Health Organization (WHO) proposedFigure 3 Histopathology of the lung tumor. Pathological tissues stained w
non-neoplastic lung tissue (NT) (A, ×20). The tumor is composed of eosino
showing a sheet-like pattern of growth (B, ×200).including the ambiguous term carcinoid in the category
of endocrine tumors. According to the 2004 WHO
classification, NE tumors (NET) in the lung were classi-
fied into small cell carcinoma, large cell neuroendo-
crine carcinoma, typical carcinoid tumor, and atypical
carcinoid tumor [16]. In this classification, the former
two tumor types (small cell and large cell neuro-
endocrine carcinomas (NECs)) were defined as poorly
differentiated NEC, whereas the latter two (typical and
atypical carcinoid tumors) were deemed endocrine tu-
mors arising in the gastrointestinal tract and defined as
well-differentiated NET.
Furthermore, in 2010, the WHO proposed giving pan-
creatic and gastrointestinal tumors with an endocrine
phenotype the name neuroendocrine neoplasms (NENs)
[17]. In this classification system, NENs are divided into
well-differentiated NETs and poorly differentiated NECs,
and the NETs are further subdivided according to the
number of mitoses and the percentage of ki67 staining,
both of which are indices of cellular proliferation.ith hematoxylin-eosin. The lung tumor (T) is well-demarcated from the
philic tumor cells with swollen ovale nuclei and prominent nucleoli
Figure 4 Immunohistochemistry of the lung tumor. The lung tumor was positive for PSA (A), synaptophysin (C), and CD56 (D), but negative for
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Figure 5 Flow chart of search strategy. Twelve articles were identified.
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fied into small cell carcinoma, carcinoid or carcinoid-
like tumor, and prostate adenocarcinoma with NED [1].
NE cells exist in the normal prostate and secrete growth
factors and cytokines, including serotonin, calcitonin, se-
cretin, and other peptide hormones. In addition, NE cells
are considered to be involved in the differentiation and
proliferation of prostatic cells through growth factors,
and these processes are not mediated by ARs [1]. How-
ever, there are various hypotheses explaining their pos-
sible histogenesis, including the following: 1) the tissues
are derived from preexisting NE cells in the prostate
gland, 2) the tissues develop through differentiation of
adenocarcinoma, and 3) the tissues arise from multi-
potential stem cells [18]. NET in prostate cancer is rare,
with reported prevalences of 0.2% to 1% [2,19]. NETs can
be classified according to the conditions at the time of de-
tection as pure NE prostate carcinoma at the time of
initial examination, mixed pattern of conventional and NE
prostatic carcinomas at the time of initial examination, or
NEC that develop during endocrine therapy. A Japanese
study found the incidence rates of these three conditions
to be 35%, 18%, and 47%, respectively [20]. Japan has a
higher incidence of NED in prostate cancer during endo-
crine therapy than other countries [2]. We speculate that,
in the present case, NE cancer developed during endo-
crine therapy for conventional prostate adenocarcinoma.
In this patient, the lung mass was not definitively diag-
nosed preoperatively. The tumor was considered to be an
adenocarcinoma replacing the alveolar lining cells based
on an intraoperative rapid diagnosis, but we were unable
Table 1 Clinical data of patients with solitary lung metastasis of prostatic cancer







Present case 50 PSA 61.7, cT4, GS4 + 5 Neoadjuvant
endocrine therapy
radiation therapy
None Left S5, 3 cm Lobectomy and
mediastinal LND








Pepe et al. [6] 2012 75 PSA 8.3, pT3a, GS4 + 3,




None Left S6, 2 cm Metastatectomy PSAP (+), TTF-1 (−) Undetectable





Left S8, 2.2 cm Wedge resection PSAP (+), P504 (+), pleural
dissemination
Undetectable


















Surgical resection Unknown Undetectable
Khandani et al. [12] 2009 78 Prostate cancer only Radiation therapy None Left S10, 5 cm Lobectomy and
mediastinal LND
PSAP (−) Undetectable




left S8, 2 cm endocrine therapy
and surgical
resection








Wedge resection PSAP (+), W-M/D adenoca 12-year disease
free follow up










Lobectomy PSAP (+), P/D adenoca Metastases,
undetectable
Smith et al. [5] 1999 70 GS4 + 5, pT2 Radical
prostatectomy
None Right S7, 2 cm Surgical resection PSAP (+), P/D adenoca Undetectable
Rockey et al. [14] 1990 83 Low grade prostate
cancer only
Radiation therapy None Left lower lobe
only
Orchiectomy PSAP (+), meta. Only Undetectable
Fabozzi et al. [3] 1995 11 cases: details unknown
Varkarakis et al. [11] 1974 One case, details unknown
‘+’, Positive; PSA: prostate-specific antigen; NEC: neuroendocrine carcinoma; NET: neuroendocrine tumor; NENs: neuroendocrine neoplasms; GS: Gleason score; PSAP: prostate-specific antigen phosphatase; CD56/57:
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at this time. Imaging studies revealed spicula, notch, and
pleural indentation findings, which also made differentiat-
ing between lung metastasis and a primary lung tumor
difficult. One reason for the difficulty in differentiating be-
tween primary and metastatic lung tumors is that the re-
placement growth of alveolar lining epithelial cells is also
observed in approximately 15% of metastatic lung tumors.
Such a growth pattern occurs in many cancers, including
colon, gallbladder, breast, gastric, prostate, thyroid, and
kidney malignancies [21]. As a result, our present patient
who was considered to have a primary lung cancer, under-
went thoracoscopic segmental resection of the lung with
lymph node dissection and then, finally, the lung mass
was diagnosed as a metastatic adenocarcinoma with NED
from the prostatic cancer.
Among the 23 case reports describing solitary lung
metastasis (including the present patient), the treatment
procedure was described for 11. Ten of these eleven pa-
tients underwent surgery, and most had good outcomes,
but there were two the exceptions (case 6 and our present
patient). In addition, the effectiveness of surgical treat-
ment for solitary metastasis from prostate cancer has also
been reported [4,22].
The present patient developed systemic metastases after
surgery, necessitating chemotherapy and radiotherapy.
This patient survived for approximately 30 months. NE
cancer in the prostate gland has been regarded as having a
poor prognosis, with reported median survival times of
9.8 months [19] and 13.1 months [23]. The relatively long
survival time in the present case may be attributable to
the pathological status of the disease; that is, the tumor
demonstrated a mixed pattern consisting of conventional
and NE prostatic carcinomas. The long-established proto-
col for patients with this condition is to administer treat-
ment that includes chemotherapy for small cell lung
cancer. Considering that the standard treatment of pul-
monary small cell carcinoma has not changed since the
1990s [24], it may be difficult to achieve prognostic im-
provement, at least for now. We therefore consider immu-
nostaining to be advisable at the time of biopsy for young
patients with high-grade tumors in order to investigate
the possible presence of NE tumors or NE components.
Establishing the correct diagnosis and implementing the
most appropriate treatment plan are important for redu-
cing the impact of this disease.
Conclusions
Solitary lung metastasis from prostate cancer is rare. We
advocate that clinicians be aware of the possible pres-
ence of metastasis from prostate cancer when a patient
has a solitary lung tumor histologically diagnosed along
with NED or has a history of prostate cancer. According
to the previously published case reports, some patientswith solitary lung metastasis from prostate cancer achieved
relatively good long-term survival. We consider establish-
ing the correct diagnosis and implementing the most ap-
propriate treatment plan to be essential in prostate cancer
patients with oligometastases, if they have a NE tumor.
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